Dr. Ibon Garitaonandia is the Chief Scientific Officer at CellProthera, a French clinical stage biotechnology company developing stem cell based therapies for cardiovascular and ischemic indications. He is conducting a Phase 2 study in post-acute myocardial infarction (NCT02669810) and preclinical studies in ischemic stroke. He was previously the Chief Science Officer at Richmond Research Institute (RRI) in London, where he conducted clinical research in cardiac health, diabetes, hepatic injury, ethnic and sex differences in physiology, and COVID-19 (NCT04404062, NCT01984827, NCT01642485, NCT04873258). Prior to joining RRI, he was Chief Scientific Officer at Histocell, a Spanish clinical stage biotechnology company developing cell based therapies for acute spinal cord injury (NCT02917291), bone regeneration (NCT02483364), and acute respiratory distress syndrome (NCT04289194). Before that, he was the Director of Translational Research at International Stem Cell Corporation, a Californian clinical stage biotechnology company developing stem cell-based therapies for Parkinson’s disease, traumatic brain injury, and stroke. He received the world’s first regulatory approval to conduct a human pluripotent stem cell based clinical trial in Parkinson’s disease (NCT02452723). He trained with  Professor Jeanne Loring at the Centre for Regenerative Medicine at The Scripps Research Institute, where he was awarded a prestigious California Institute for Regenerative Medicine Postdoctoral Fellowship and collaborated with Nobel Laureates Professor Shinya Yamanaka and Professor Gerald Edelman. Dr. Ibon Garitaonandia graduated in Chemistry from the University of the Basque Country and received his PhD in Biochemistry from the University of Florida. He has given numerous oral presentations at international conferences including Society for Neuroscience, International Society for Cellular Therapy, and American Society of Gene & Cell Therapy and has authored book chapters and several peer-reviewed publications. He is the co-inventor of eight patents and a member of the International Society for Stem Cell Research and American Chemical Society.

Find also